Acute ischemic stroke
Conditions
Interventions
Aspirin group:Nil
Tirofiban group:Nil
Sponsors
The Second Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Aged >= 18 years; 2) The time from onset to group treatment is within 24h;The onset time of progressive stroke was calculated from the aggravation of symptoms. 3) Acute ischemic stroke was preliminarily judged according to clinical symptoms or imaging examination; 4) Brain CT confirmed ischemic stroke; 5) Non-large vessel occlusive stroke confirmed by CTA/MRA/DSA;(Note: Great vessels are defined as internal carotid artery (ICA), vertebral artery (VA) V1-V4, basilar artery (BA), posterior cerebral artery (PCA) P1, anterior cerebral artery (ACA) A1, middle cerebral artery (MCA) M1, M2, and extracranial and intracranial segments). 6) Written informed consent signed by the patient or family member.
Exclusion criteria
Exclusion criteria: 1) Pre-onset MRS score >= 2 points; 2) Pregnant or lactating women; 3) Imaging confirmed cerebral hemorrhage; 4) Patients with allergies or allergies to tirofiban, contrast agent, aspirin and clopidogrel, as well as contraband for the use of the above drugs; 5) Take dual antiplatelet drugs within one week before onset; 6) MRI DWI imaging or clinical symptoms are consistent with posterior circulation ischemic stroke; 7) Have received intravenous thrombolytic therapy with alteplase or urokinase; 8) Systolic blood pressure > 185mmHg or diastolic blood pressure BBB > 0 mmHg, which could not be controlled by oral antihypertensive drugs; 9) genetic or acquired bleeding constitution, lack of anticoagulant factors;Or oral anticoagulant and INR>1.7; 10) Blood glucose 22.2mmol/L (400mg/ dL), platelet 3 times the upper normal limit or AST BBB>times the upper normal limit;Chronic hemodialysis and severe renal insufficiency (glomerular filtration rate 220µmol/L (2.5mg/ dL)); 13) of atherosclerotic lesions, including: artery dissection, moya - moya disease, vasculitis, herpes zoster, varicella zoster disease or other viral vascular disease and nerve syphilis, any other intracranial infection, associated with pleocytosis any vascular stenosis, vascular lesions induced by radiation, muscular fiber dysplasia, sickle cell disease, neurofibromatosis, benign vascular disease of the central nervous system, postnatal vascular disease, suspected of vasospasm, suspicious embolus recanalization; 14) Cardiogenic stroke or potential cardiogenic thrombosis with any of the following clear causes of cardiogenic embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valves, endocarditis, intracardiac thrombosis or implants, dilated cardiomyopathy, spontaneous acoustic imaging of the left atrium; 15) Any history of cerebral parenchyma or other intracranial subarachnoid space, subdural or epidural blood within the last 30 days; 16) Myocardial infarction within the last 30 days; 17) Major surgery (including open femoral artery, aorta, carotid, subclavian or intracranial artery bypass surgery, etc.) and cerebrovascular angioplasty (balloon or stent implantation) are planned within 90 days; 18) Ejection fraction < 40%, insufficiency of heart, lung and other important organs; 19) current severe alcohol dependence or drug abuse; 20) Alzheimer's disease or mental illness affects patients' reliable adherence to the follow-up plan; 21) Life expectancy of any terminal disease < 6 months; 22) The follow-up is not expected to be completed; 23) Intracranial aneurysm, arteriovenous malformation; 24) Brain tumors with mass effect on imaging.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRS at 90 days;The incidence of symptomatic intracranial hemorrhage (SICH) within 48 hours after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of complications of non-intracranialhemorrhage;Thrombocytopenia.;Improvement in 90-day MRS scores;90-day EQ-5D scale score; | — |
Countries
China
Contacts
Public ContactQingwu Yang
The Second Affiliated Hospital of the Army Medical University
Outcome results
None listed